We (the entity) give ASX the following information.
Information about buy-back
Type of buy-back
Date Appendix 3C was given to ASX
On-market
9 December 2020
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day
Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received
Total consideration paid or payable for the shares/units
Before previous day
Previous day
9,125,414268,291
A$36,834,939.90A$1,092,427.29
+ See chapter 19 for defined terms.
11/01/2010
Appendix 3E Page 1
Appendix 3E
Daily share buy-back notice
5 If buy-back is an on-marketbuy-back
Before previous day
Previous day
highest price paid:
4.260
highest price paid:
4.100
date:
25-Mar-21
lowest price paid:
3.725
lowest price paid:
4.030
date:
30-Dec-20
highest price allowed
under rule 7.33:
4.2830
Participation by directors
6 Deleted 30/9/2001.
How many shares/units may still be bought back?
7 If the company/trust has disclosed an intention to buy back a maximum number of shares/units - the remaining number of shares/units to be
bought back
No specific number of shares, but the number of shares required to achieve up to $200,000,000 in consideration provided that the total number of shares bought back is within the 10/12 limits of the announced Appendix 3C
Compliance statement
1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
or, for trusts only:
The trust is in compliance with all requirements of the Corporations Act as modified by
Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.
Sign here:
……………………………………
Date: 16/04/2021
Company Secretary
Print name:
Charles Tilley
+ See chapter 19 for defined terms.
Appendix 3E Page 2
11/01/2010
Attachments
Original document
Permalink
Disclaimer
Healius Limited published this content on 16 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 April 2021 14:36:07 UTC.
Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories, collection centers, and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. The Companyâs brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. The Company provides healthcare services that are accessible and efficient while supporting the coordination and continuity of quality patient care.
HEALIUS LIMITED 
